Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vistusertib in Japanese patients with advanced solid malignancies
NCT02398747Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2015
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of vistusertib in solid tumor (advanced stage) (3 arms), sponsored by AstraZeneca. Primary endpoint: Safety and tolerability measured by adverse events at 6 months. Started Mar 2015; status: completed.
02
Drugs
vistusertib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02398747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02398747.